A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

109

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions

Cystic Fibrosis

Interventions

DRUG

FDL176

CFTR modulator

DRUG

Placebo

Placebo for FDL176

Trial Locations (3)

Wayne Hooper Clinic Clive Berghofer Cancer research Center, Herston

Mater Hospital, South Brisbane

Linear Clinical Research, Perth

All Listed Sponsors

lead

Flatley Discovery Lab LLC

OTHER

NCT03173573 - A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants | Biotech Hunter | Biotech Hunter